CT-4201

CT-4201
Clinical data
Other namesCT4201
Drug classNon-selective serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code
  • None

CT-4201 is a serotonergic psychedelic which is under development for the treatment of major depressive disorder.[1][2][3] It is a prodrug of the tryptamine psychedelic psilocin that is said to have improved pharmacokinetic properties compared to psilocybin, the primary active constituent of psilocybin-containing mushrooms.[1][2][3][4][5] CT-4201 is being developed by CaaMTech.[1][2][3] As of November 2024, it is in the preclinical research stage of development.[1][2]

See also

References

  1. ^ a b c d "Delving into the Latest Updates on CT-4201 with Synapse". Synapse. 8 May 2025. Retrieved 1 August 2025.
  2. ^ a b c d Haichin M. "Psychedelics Drug Development Tracker". Psychedelic Alpha. Retrieved 1 August 2025.
  3. ^ a b c "FDA Endorses CaaMTech's Psilocin Drug Development For Depression Treatment". Sahm. 14 November 2024. Retrieved 1 August 2025.
  4. ^ "CaaMTech receives FDA endorsement for psilocin depression drug development". SPEEDA Edge. 14 November 2024. Retrieved 1 August 2025.
  5. ^ "CaaMTech Receives Regulatory Validation for Functional Unblinding Strategy in Psilocin Prodrug Trial". MedPath. 15 November 2024. Retrieved 1 August 2025.


This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.